A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.

J Cancer Res Ther

Division of Radiation Oncology, Nanavati Hospital, Vile Parle (W), Mumbai, India.

Published: January 2008

Purpose: To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease.

Materials And Methods: Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.

Results: All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.

Conclusion: Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.

Download full-text PDF

Source
http://dx.doi.org/10.4103/0973-1482.16089DOI Listing

Publication Analysis

Top Keywords

tocoferol monoglucoside
12
hemi-body radiation
12
phase trial
8
undergoing hemi-body
8
accrued study
8
study patients
8
patients
6
radiation
6
trial tocoferol
4
monoglucoside patients
4

Similar Publications

Purpose: To investigate the effects of electromagnetic pulses (EMP) on associative learning in mice and test a preliminary mechanism for these effects.

Materials And Methods: A tapered parallel plate gigahertz transverse electromagnetic (GTEM) cell with a flared rectangular coaxial transmission line was used to expose male BALB/c mice to EMP (peak-intensity 400 kV/m, rise-time 10 ns, pulse-width 350 ns, 0.5 Hz and total 200 pulses).

View Article and Find Full Text PDF

The effects of TMG [2-(alpha-d-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol], a water-soluble vitamin E derivative, administered after irradiation on the mortality of X-irradiated mice and on the development of tumors in the mammary and pituitary glands in rats were investigated. When TMG (650 mg/kg) was administered intraperitoneally (i.p.

View Article and Find Full Text PDF

Background: Cisplatin is one of the most widely used cytotoxic therapeutic agents for the treatment of cancer. This drug, at effective higher doses, causes many physiological adverse effects such as nephrotoxicity and genotoxicity. The toxicity of the drug has been attributed to the induction of oxidative free radicals.

View Article and Find Full Text PDF

A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.

J Cancer Res Ther

January 2008

Division of Radiation Oncology, Nanavati Hospital, Vile Parle (W), Mumbai, India.

Purpose: To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease.

View Article and Find Full Text PDF

A preparation of alpha-tocopherol monoglucoside (TMG) administered i.p. at a dose of 600 mg/kg immediately after whole body gamma irradiation was examined for its radioprotective efficacy towards bone marrow and peripheral blood nucleated cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!